Table 2.
Nomenclature of TCRvβ targets and antibodies used
| TCRvβ antibody | Gene name(s) | Clone | Tube; fluorochrome | Targets used in this report |
|---|---|---|---|---|
| TCRvβ 1 | TRBV9 | F; PE + FITC | ||
| TCRvβ 2 | TRBV20-1 | E; PE + FITC | ||
| TCRvβ 3 | TRBV28 | A; FITC | ||
| TCRvβ 4 | TRBV29-1 | P-LS-01 | H; PE + FITC | Healthy T cells (fratricide) |
| TCRvβ 5.1 | TRBV5-1 | P-LS-02 | C; PE + FITC |
Healthy T cells (fratricide); patient cells |
| TCRvβ 5.2 | TRBV5-6 | E; PE | ||
| TCRvβ 5.3 | TRBV5-5 | A; PE | ||
| TCRvβ 7.1 | TRBV4-1, 4-2, 4-3 | A; PE + FITC | ||
| TCRvβ 7.2 | TRBV4-3 | P-LS-03 | H; FITC | Healthy T cells (fratricide) |
| TCRvβ 8 | TRBV12-3, 12-4 | D; FITC | ||
| TCRvβ 9 | TRBV3-1 | P-LS-04 | B; PE |
Healthy T cells (fratricide); engineered cell line |
| TCRvβ 11 | TRBV25-1 | G; PE | ||
| TCRvβ 12 | TRBV10-3 | P-LS-05 | E; FITC |
Healthy T cells (fratricide); engineered cell line; patient cells |
| TCRvβ 13.1 | TRBV6-5, 6-6, 6-9 | D; PE | ||
| TCRvβ 13.2 | TRBV6-2 | P-LS-06 | H; PE | Healthy T cells (fratricide) |
| TCRvβ 13.6 | TRBV6-6 | D; PE + FITC | ||
| TCRvβ 14 | TRBV27 | G; FITC | ||
| TCRvβ 16 | TRBV14 | B; FITC | ||
| TCRvβ 17 | TRBV19 | B; PE + FITC | ||
| TCRvβ 18 | TRBV18 | C; PE | ||
| TCRvβ 20 | TRBV30 | C; FITC | ||
| TCRvβ 21.3 | TRBV11-2 | F; FITC | ||
| TCRvβ 22 | TRBV2 | P-LS-07 | G; PE + FITC | Healthy T cells |
| TCRvβ 23 | TRBV13 | F; PE |
Sequences derived from bolded antibodies were used in CAR design.
FITC, fluorescein isothiocyanate; PE, phycoerythrin; TRBV, T-cell receptor beta variable.